| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5845493 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2011 | 5 Pages |
Abstract
âºFunctional interaction (FI) between glutamate and cannabidiol (CBD) receptors contributes to the etiology of schizophrenia. âºIt is important to understand the mechanism of action related to the FI of ketamine and CBD in humans. âºInvestigating the FI of CBD and ketamine in humans may further clarify the interplay of CB1/2 and NMDA receptors. âºStudy shows that a complex FI between CBD and ketamine exists. âºUnderstanding such FI may lead to new pharmacotherapy for schizophrenia.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Jaime E.C. Hallak, Serdar M. Dursun, Daniel C. Bosi, Ligia Ribeiro Horta de Macedo, João Paulo Machado-de-Sousa, João Abrão, José A.S. Crippa, Phillip McGuire, John H. Krystal, Glen B. Baker, Antonio W. Zuardi,